Multiple Sclerosis

Higher Sun Exposure Tied to Lower Risk of Multiple Sclerosis

March 08, 2018

Findings based on sun exposure at 5 to 15 years of age and at 5 to 15 years before MS onset

Multiple Sclerosis Drug Being Pulled from the Market

By March 02, 2018

Because of its safety profile, the use of Zinbryta is generally reserved for patients who have had an inadequate response to 2 or more MS drugs.

New Strength of Glatopa Available for Relapsing MS

By February 13, 2018

Sandoz GlatopaCare will offer a $0 co-pay support program to qualified patients.

Fetal Risk After Pregnancy Exposure to Natalizumab Examined

February 08, 2018

And, natalizumab washout period is only predictor of relapse occurrence during pregnancy

Rituximab associated with lower drug discontinuation and disease relapse rates in multiple sclerosis

January 10, 2018

Rituximab was associated with lower discontinuation rates as compared to other disease-modifying treatments in newly diagnosed patients with relapsing-remitting multiple sclerosis.

First-Line Disease-Modifying Txs Compared for Relapsing-Remitting MS

January 09, 2018

Of the 494 patients, 43.5% received an injectable DMT, 17.4% dimethyl fumarate, 3.4% fingolimod, 10.1% natalizumab, 24.3% rituximab, and 1.2% other DMT.

Fingolimod Gets Breakthrough Therapy Designation for Pediatric MS

By December 18, 2017

The FDA has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple sclerosis (MS).

Do Certain Medications Increase the Risk of MS Development?

By December 07, 2017

No drug treatments were conclusively associated with an increased risk of MS.

Diet Quality May Affect MS Disability Severity

December 07, 2017

The researchers found that having dietary quality scores in the highest versus the lowest quintile correlated with lower levels of disability.

Percutaneous Transluminal Angioplasty Examined in MS Patients

November 27, 2017

There was no difference in the composite functional measure (walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity) between the PTA and sham groups (41.7 vs. 48.7%; odds ratio, 0.75; 95% confidence interval, 0.34 to 1.68; P=0.49).

Positive Results for Fingolimod in Pediatric Patients With Relapsing MS

By October 30, 2017

Children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Novel MS Drug Candidate Effective in Relapsing MS

By October 27, 2017

Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator.

MS Outcomes Examined After Switching from Interferon Beta-1a to Alemtuzumab

By October 27, 2017

Approximately 80% of patients from the CARE-MS I trial (n=139) and the CARE-MS II trial (n=143) had elected to enter the extension phase of the study.

Ocrelizumab Significantly Reduced PIRA in Patients With Relapsing MS

By October 27, 2017

Data show superiority of Ocrevus compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS)

Teriflunomide May Delay Conversion to Clinically Definite MS

By October 26, 2017

The overall two-year data showed that compared to placebo, Aubagio significantly reduced cortical gray matter volume (CGMV) loss (Aubagio 7mg, P=0.0089; Aubagio 14mg, P=0.0052) and the risk of CDMD conversion.

MS-Related Fatigue Reduced With Transcranial Direct Current Stimulation

By October 04, 2017

Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System.

Mylan Gets Approval for Generic Versions of Two Copaxone Strengths

By October 04, 2017

The mechanism by which glatiramer acetate exerts its therapeutic effect in MS is unknown, however it is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.

Vit D Deficiency: A Risk Factor for MS?

By September 21, 2017

Data showed that a 50nmol/L increase in 25(OH)D correlated with a 39% decreased risk of MS. Specifically, a 43% increased risk of MS was seen in women with 25(OH)D levels <30nmol/L vs. women with levels ≥50nmol/L.

Multiple Sclerosis Treatment Highlights

By September 13, 2017

MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.

Epstein-Barr Virus May Increase Risk for Multiple Sclerosis

August 31, 2017

The researchers found that those with MS in all three racial groups were more likely to show signs of infection with EBV.

Dimethyl Fumarate and Oral Contraceptives: Drug Interactions Explored

By August 08, 2017

Delayed-release DMF exerts anti-inflammatory and neuroprotective properties for the treatment of relapsing multiple sclerosis, a disease that often develops in women between the ages of 20 and 40.

MS Risk May Be Lower for Mothers Who Breastfeed

July 13, 2017

Benefits reported for women who nursed 15 months or more

Ocrevus Effective in Reducing Multiple MS Progression Markers

By June 23, 2017

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.

Brain Changes in MS Linked to Social Cognition Impairment

June 02, 2017

Diffuse normal-appearing white matter damage may create disconnection in social brain network

Minocycline May Benefit in Early Multiple Sclerosis

June 01, 2017

Treatment with minocycline reduces conversion to MS over six months after first demyelinating event

FDA Approves App to Help Guide MS Patient Care with Betaseron

By May 31, 2017

This new software allows patients currently using the electronic BETACONNECT autoinjector to administer Betaseron (interferon beta-1b) to connect their autoinjector to the new myBETAapp through their mobile device or computer.

Novel Oral Therapy Looks Promising for Relapsing MS

By May 22, 2017

The Radiance trial included 1,313 relapsing multiple sclerosis (RMS) patients who were administered either 0.5mg or 1mg of oral ozanimod, or weekly intramuscular interferon beta-1a (Avonex) over a 2 year treatment period.

Pharmacist Program Demonstrates Benefits for MS Patients

May 17, 2017

Cheong noted that only 1 patient was non-adherent. There was an increase in patient knowledge scores, from a mean baseline score of 20.14 to 31.67 (P<0.05) by the end of the third appointment.

Additional Data Support Ocrevus Safety, Efficacy in MS

By April 27, 2017

Among patients with early relapsing multiple sclerosis patients, Ocrevus suppressed >90% of active MRI lesions over 2 years vs. interferon beta-1a.

Long-Term Data Show Benefits of Lemtrada in RRMS

By April 26, 2017

The majority of patients who relapsed between courses were free of confirmed disability worsening (CDW) in Year 2 and 60% remained free of CDW by Year 6.